Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

An Analysis of Real Life Data Obtained from 30 Years Follow-up of Primary Myelodysplastic Syndromes (MDS) Patients Confirms a Leading Role of Stem Cell Transplantation (SCT) for Achievement of Prolonged Survival

Jaroslav Cermak, MD PhD, Antonin Vitek, MD, Dana Mikulenkova, MD, Jacqueline Soukupova, MD, Jana Brezinova, Marketa Stastna, MD PhD, Veronika Valkova, MD PhD, Monika Belickova, PhD, Kyra Michalova, PhD, Petr Cetkovsky, MD MBA, PhD

Blood (2018) 132 (Supplement 1): 4372.

https://doi.org/10.1182/blood-2018-99-114987

Published: 2018

Journal Articles

Chromothripsis in High-Risk Myelodysplastic Syndromes: Incidence, Genetic Features, Clinical Implications, and Impact on Survival of Patients Treated with Azacytidine (Data from Czech MDS Group)

Zuzana Zemanova, PhD, Kyra Michalova, PhD, Karla Svobodova, Jana Brezinova, Halka Lhotska, PhD, Libuse Lizcova, PhD, Iveta Sarova, PhD, Silvia Izakova, Lucie Hodanova, PhD, Denisa Vesela, Sarka Ransdorfova, Monika Belickova, PhD, Jitka Vesela, MSc, Helena Polackova, Magda Siskova, MD, Radana Neuwirtova, MD PhD, Jaroslav Cermak, MD PhD, Tomas Stopka, MD PhD, Anna Jonasova, MD

Blood (2018) 132 (Supplement 1): 1815.

https://doi.org/10.1182/blood-2018-99-114151

Published: 2018

Journal Articles

Importance of Transcription Factor Nrf2 for Cereblon Expression and Clinical Response to Combination of Lenalidomide and Erythropoietin in Lower-Risk Myelodysplastic Syndromes

Radka Bokorová, MSc, Jaroslav Polak, MSc, Anna Jonasova, MD, Radana Neuwirtova, MD PhD, Marie Lauermannova, MD, Jaroslav Cermak, MD PhD, Marketa Stastna, MD PhD, Cyril Salek, Dana Mikulenkova, MD, Zuzana Zemanova, PhD, Jana Brezinova, Kyra Michalova, PhD, Denisa Myslivcova, PhD, Ota Fuchs, PhD

Blood (2018) 132 (Supplement 1): 5507.

https://doi.org/10.1182/blood-2018-99-115803

Published: 2018

Journal Articles

Frequency and Clinical Impact of Cytogenetic Clonal Evolution in Myelodysplastic Syndromes (MDS) with Isolated Del(5q)

Zuzana Zemanova, PhD, Kyra Michalova, PhD, Jana Brezinova, PhD, Karla Svobodova, Halka Lhotska, Iveta Sarova, PhD, Libuse Lizcova, PhD, Silvia Izakova, Sarka Ransdorfova, PhD, Lenka Pavlistova, PhD, Adela Berkova, PhD, Karolina Skipalova, Monika Belickova, PhD, Magda Siskova, MD, Radana Neuwirtova, MD PhD, Jaroslav Cermak, MD PhD, Tomas Stopka, MD PhD, Anna Jonasova, MD PhD

Blood (2016) 128 (22): 1982.

https://doi.org/10.1182/blood.V128.22.1982.1982

Published: 2016

Journal Articles

Somatic Genetic and Epigenetic Architecture of Myelodysplastic Syndromes Arising from GATA2 Deficiency

Victor Bengt Pastor Loyola, MSc, Shinsuke Hirabayashi, MD, Sandra Pohl, PhD, Emilia J Kozyra, MSc, Albert Catala, MD, Barbara De Moerloose, MD PhD, Michael Dworzak, MD, Henrik Hasle, MD, Riccardo Masetti, MD, Markus Schmugge, MD, Owen Smith, Jan Starý, MD, Marek Ussowicz, MD, Marry M. van den Heuvel-Eibrink, MD PhD, Ester Mejstrikova, MD PhD, Ulrich Salzer, MD, Michael Lübbert, MD, Daniel Heudobler, MD, David Betts, MD, Jose Cervera, MD, Gudrun Göhring, MD, Oskar A. Haas, Olga Haus, MD, Kyra Michalova, PhD DSc, Francesco Pasquali, MD, Joelle Tchinda, MD, Nadine van Roy, MD, Brigitte Schlegelberger, MD Prof., H. Berna Beverloo, PhD, Peter Noellke, MSc, Ayami Yoshimi, MD, Franco Locatelli, Prof, MD PhD, Brigitte Strahm, MD, Jaroslaw P. Maciejewski, MD PhD, Michael Rehli, PhD, Charlotte M Niemeyer, Prof, MD, Marcin W Wlodarski, MD

Blood (2015) 126 (23): 299.

https://doi.org/10.1182/blood.V126.23.299.299

Published: 2015

Journal Articles

The ASXL1 Gene Alterations in Patients with Myeloid Diseases and Chromosomal 20q Deletion

Jana Brezinova, PhD, Iveta Sarova, PhD, Halka Lhotska, Sarka Ransdorfova, PhD, Silvia Izakova, Karla Svobodova, Jana Markova, Zuzana Zemanova, Ass. Prof.,PhD, Jaroslav Cermak, MD PhD As. Prof., Anna T. Jonasova, MD, Kyra Michalova, PhD Prof.

Blood (2014) 124 (21): 5596.

https://doi.org/10.1182/blood.V124.21.5596.5596

Published: 2014

Journal Articles

Hematopoietic Cell Transplantation after TBI, Fludarabine, Idarubicine and Cytarabine Myeloablative Conditioning in Patients with Acute Myeloid Leukemia

Jan Vydra, MD, Veronika Válková, MD, Markéta ťastná Marková, MD, Ludmila Nováková, MD, Jiří Schwarz, MD PhD, Cyril álek, MD PhD, Antonín Vítek, MD, Petr Cetkovský, MD PhD Prof., Jaroslav Čermák, MD PhD, Kyra Michalová, Prof.

Blood (2014) 124 (21): 5847.

https://doi.org/10.1182/blood.V124.21.5847.5847

Published: 2014

Journal Articles

The Good Prognosis and Positive Response to the Therapy of Patients with Two Unrelated Clones Del(5q) and Trisomy 8 Does Not Differ to That of the 5q- Syndrome. This Is in Contrast to the Bad Prognosis of Patients with the Same Chromosomal Aberrations in One Clone

Radana Neuwirtova, MD PhD As. Prof., Zuzana Zemanova, Jana Brezinova, PhD, Pavel Dvorak, MD, Ota Fuchs, PhD, Martin Vostry, Anna T Jonasova, MD, Jaroslav Cermak, MD PhD As. Prof., Dana Sponerova, MD, Zuzana Maskova, MD, Libor Cervinek, MD PhD, Vera Vozobulova, MD, Eva Polonyova, MD, Kyra Michalova, PhD Prof.

Blood (2014) 124 (21): 5626.

https://doi.org/10.1182/blood.V124.21.5626.5626

Published: 2014

Journal Articles

Clonal Heterogeneity in Patients with Myelodysplastic Syndromes (MDS) and Complex Karyotypes

Zuzana Zemanova, Ass. Prof.,PhD, Kyra Michalova, PhD Prof., Jana Brezinova, PhD, Halka Lhotska, Karla Svobodova, Iveta Sarova, PhD, Libuse Lizcova, PhD, Silvia Izakova, Sarka Ransdorfova, PhD, Zdenek Krejcik, PhD, Monika Belickova, PhD, Magda Siskova, MD, Anna Jonasova, MD, Radana Neuwirtova, MD PhD As. Prof., Jana Zmolikova, Jaroslav Cermak, MD PhD As. Prof.

Blood (2014) 124 (21): 859.

https://doi.org/10.1182/blood.V124.21.859.859

Published: 2014

Journal Articles

The Significance Of Fli1 and p53 For The Effective Megakaryopoiesis In 5q- Syndrome and The Effect Of Lenalidomide Treatment

Radana Neuwirtova, MD, PhD, Jan Stritesky, MD, PhD, Ota Fuchs, PhD, Martin Vostry, Arnost Kostecka, Monika Belickova, PhD, Magdalena Siskova, MD, PhD, Kyra Michalova, prof., PhD, Jaroslav Cermak, Ass. Prof., PhD, Anna T Jonasova, MD

Blood (2013) 122 (21): 5208.

https://doi.org/10.1182/blood.V122.21.5208.5208

Published: 2013

Journal Articles

High Cereblon Expression In Lower Risk Myelodysplastic Syndromes With 5q Deletion Is Associated With The Efficacy Of Lenalidomide

Anna T Jonasova, MD, Jaroslav Polak, Martin Vostry, Arnost Kostecka, Radka Bokorova, Radana Neuwirtova, MD, PhD, Magda Siskova, MD, Miroslav Caniga, Dana Sponerova, Jaroslav Cermak, Dana Mikulenková, MD, Jana Brezinova, PhD, Kyra Michalova, PhD, Ota Fuchs, PhD

Blood (2013) 122 (21): 1529.

https://doi.org/10.1182/blood.V122.21.1529.1529

Published: 2013

Journal Articles

Putative Monosomy 5 In Myelodysplastic Syndromes (MDS) Is Probably Resulting From Chromothripsis

Zuzana Zemanova, Kyra Michalova, PhD, Halka Buryova, Jana Brezinova, PhD, Libuse Lizcova, Karla Kostylkova, Iveta Sarova, PhD, Silvia Izakova, Sarka Ransdorfova, Zdenek Krejcik, Michaela Dostalova Merkerova, PhD, Magda Siskova, MD, Anna T Jonasova, MD, Radana Neuwirtova, MD, PhD, Jaroslav Cermak, PhD

Blood (2013) 122 (21): 1559.

https://doi.org/10.1182/blood.V122.21.1559.1559

Published: 2013

Journal Articles

A reclassification of Myelodysplastic Syndrome (MDS) patients of RAEB-1 subgroup according to IPSS-R improves discrimination of high risk patients and better predicts overall Survival. A retrospective analysis of 49 Patients

Jaroslav Cermak, MD, PhD, Dana Mikulenková, MD, Jana Brezinova, MD, PhD, Kyra Michalova, prof., PhD

Blood (2012) 120 (21): 4957.

https://doi.org/10.1182/blood.V120.21.4957.4957

Published: 2012

Journal Articles

The Significance of Megakaryocytic Transcription Factor Fli1 and Erythroid Transcription Factor EKLF in the Ribosomopathies: 5q Minus Syndrome and Diamond-Blackfan Anemia. the Role of Fli1 in p53 Regulation and in 5q Minus Syndrome Megakaryopoiesis,

Radana Neuwirtova, MD, PhD, Ota Fuchs, PhD, Dagmar Pospisilova, MD, PhD, Radek Cmejla, PhD, Monika Holicka, Martin Vostry, Arnost Kostecka, Hana Hajkova, Anna Jonasova, MD, Jaroslav Cermak, MD, PhD, Kyra Michalova, PhD, Jana Brezinova, PhD

Blood (2011) 118 (21): 3825.

https://doi.org/10.1182/blood.V118.21.3825.3825

Published: 2011

Journal Articles

Changes in Gene Expression Profiles in Patients with 5q- Syndrome Caused by Lenalidomide Treatment

Monika Belickova, Jaroslav Cermak, Jitka Vesela, Eliska Cechova, Zuzana Zemanova, Kyra Michalova, PhD, Michaela Dostalova Merkerova, Anna Jonasova, MD

Blood (2011) 118 (21): 5023.

https://doi.org/10.1182/blood.V118.21.5023.5023

Published: 2011

Journal Articles

DNMT3A Mutations Are Connected with Lower DNA Methylation Levels and Numbers of Concurrently Hypermethylated Genes in AML Patients

Hana Hajkova, Jana Markova, Cedrik Haskovec, PhD, Jaroslav Cermak, Radka Petrbokova, Kyra Michalova, PhD, Jiri Schwarz, MD, PhD

Blood (2011) 118 (21): 4629.

https://doi.org/10.1182/blood.V118.21.4629.4629

Published: 2011

Journal Articles

The Outcome of Unselected Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib In the First Line and the Prognostic Value of ELN Defined Responses – Population Based Analysis of 458 Patients Treated Between 2003–2009.

Blood (2010) 116 (21): 1239.

https://doi.org/10.1182/blood.V116.21.1239.1239

Published: 2010

Journal Articles

Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome

Blood (2010) 116 (19): 3766–3769.

https://doi.org/10.1182/blood-2010-04-280313

Published: 2010

Includes: Supplemental data

Journal Articles

Frequency and Prognostic Impact of Complex Chromosomal Aberrations in Patients with Primary Myelodysplastic Syndromes and Del(5q).

Zuzana Zemanova, Ass.Prof., Ph.D., Kyra Michalova, Prof., PhD., Jana Brezinova, Libuse Lizcova, Silvia Izakova, Dagmar Bystricka, PhD, Iveta Sarova, Adela Berkova, MD, Magda Siskova, MD, Radana Neuwirtova, MD, PhD, Olga Cerna, MD, Jaroslav Cermak, M.D., Ph.D.

Blood (2009) 114 (22): 1623.

https://doi.org/10.1182/blood.V114.22.1623.1623

Published: 2009

Journal Articles

Composition of Cellular Subsets by Flow Cytometry Identifies Differences Between MDS Subtypes and Aplastic Anemia but No Differences Are Identified Between Cases with and without Monosomy 7.

Blood (2009) 114 (22): 3802.

https://doi.org/10.1182/blood.V114.22.3802.3802

Published: 2009

NARROW

An Analysis of Real Life Data Obtained from 30 Years Follow-up of Primary Myelodysplastic Syndromes (MDS) Patients Confirms a Leading Role of Stem Cell Transplantation (SCT) for Achievement of Prolonged Survival

Chromothripsis in High-Risk Myelodysplastic Syndromes: Incidence, Genetic Features, Clinical Implications, and Impact on Survival of Patients Treated with Azacytidine (Data from Czech MDS Group)

Importance of Transcription Factor Nrf2 for Cereblon Expression and Clinical Response to Combination of Lenalidomide and Erythropoietin in Lower-Risk Myelodysplastic Syndromes

Frequency and Clinical Impact of Cytogenetic Clonal Evolution in Myelodysplastic Syndromes (MDS) with Isolated Del(5q)

Somatic Genetic and Epigenetic Architecture of Myelodysplastic Syndromes Arising from GATA2 Deficiency

The ASXL1 Gene Alterations in Patients with Myeloid Diseases and Chromosomal 20q Deletion

Hematopoietic Cell Transplantation after TBI, Fludarabine, Idarubicine and Cytarabine Myeloablative Conditioning in Patients with Acute Myeloid Leukemia

The Good Prognosis and Positive Response to the Therapy of Patients with Two Unrelated Clones Del(5q) and Trisomy 8 Does Not Differ to That of the 5q- Syndrome. This Is in Contrast to the Bad Prognosis of Patients with the Same Chromosomal Aberrations in One Clone

Clonal Heterogeneity in Patients with Myelodysplastic Syndromes (MDS) and Complex Karyotypes

The Significance Of Fli1 and p53 For The Effective Megakaryopoiesis In 5q- Syndrome and The Effect Of Lenalidomide Treatment

High Cereblon Expression In Lower Risk Myelodysplastic Syndromes With 5q Deletion Is Associated With The Efficacy Of Lenalidomide

Putative Monosomy 5 In Myelodysplastic Syndromes (MDS) Is Probably Resulting From Chromothripsis

A reclassification of Myelodysplastic Syndrome (MDS) patients of RAEB-1 subgroup according to IPSS-R improves discrimination of high risk patients and better predicts overall Survival. A retrospective analysis of 49 Patients

The Significance of Megakaryocytic Transcription Factor Fli1 and Erythroid Transcription Factor EKLF in the Ribosomopathies: 5q Minus Syndrome and Diamond-Blackfan Anemia. the Role of Fli1 in p53 Regulation and in 5q Minus Syndrome Megakaryopoiesis,

Changes in Gene Expression Profiles in Patients with 5q- Syndrome Caused by Lenalidomide Treatment

DNMT3A Mutations Are Connected with Lower DNA Methylation Levels and Numbers of Concurrently Hypermethylated Genes in AML Patients

The Outcome of Unselected Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib In the First Line and the Prognostic Value of ELN Defined Responses – Population Based Analysis of 458 Patients Treated Between 2003–2009.

Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome

Frequency and Prognostic Impact of Complex Chromosomal Aberrations in Patients with Primary Myelodysplastic Syndromes and Del(5q).

Composition of Cellular Subsets by Flow Cytometry Identifies Differences Between MDS Subtypes and Aplastic Anemia but No Differences Are Identified Between Cases with and without Monosomy 7.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only